Satsuma Pharmaceuticals Inc. (NASDAQ:STSA) Relative Strength Index (RSI) is 67.46, with weekly volatility at 8.46% and ATR at 0.50. The STSA stock’s 52-week price range has touched low of $3.50 and a $36.10 high. Intraday shares traded counted 0.29 million, which was 38.43% higher than its 30-day average trading volume of 474.04K. Its shares traded higher over the last trading session, gaining 0.43% on 02/16/21. The shares fell to a low of $6.80 before closing at $6.96. STSA’s previous close was $6.93 while the outstanding shares total 17.42M. The firm
Investors have identified the Biotechnology company Satsuma Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $124.24 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Satsuma Pharmaceuticals Inc. (STSA) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For STSA, the company has in raw cash 41.52 million on their books with 1.99 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 90.05 million total, with 7.69 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -1.06 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on STSA sounds very interesting.
Is the stock of STSA attractive?
In related news, Chief Financial Officer, O’Neil Thomas P. sold 750 shares of the company’s stock in a transaction that recorded on Sep 01. The sale was performed at an average price of 22.19, for a total value of 16,645. As the sale deal closes, the Chief Medical Officer, ALBRECHT DETLEF now sold 1,000 shares of the company’s stock, valued at 22,210. Also, Chief Financial Officer, O’Neil Thomas P. sold 1,000 shares of the company’s stock in a deal that was recorded on Aug 05. The shares were price at an average price of 25.00 per share, with a total market value of 25,000. Following this completion of acquisition, the Chief Medical Officer, ALBRECHT DETLEF now holds 1,000 shares of the company’s stock, valued at 22,906. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.10%.
0 out of 3 analysts covering the stock have rated it a Buy, while 2 have maintained a Hold recommendation on Satsuma Pharmaceuticals Inc.. 1 analysts has assigned a Sell rating on the STSA stock. The 12-month mean consensus price target for the company’s shares has been set at $4.50.